MCK vs COR vs MDLN Stock Comparison

Mckesson, Cencora and Medline Prices as of Nov 13, 2026 Peers: Industry group
MCK Mckesson Corp
$1,102.82 +12.7% 1M +30.3% 1Y
Market cap
$129.46B
P/E
27.5x
Revenue (TTM)
$418.79B
Div. yield
0.00%
Drug Distribution Healthcare
8 wins
COR Cencora, Inc.
$359.02 +6.8% 1M -1.8% 1Y
Market cap
$69.52B
P/E
22.6x
Revenue (TTM)
$337.40B
Div. yield
–
Drug Distribution Healthcare
2 wins
MDLN Medline Inc.
$39.47 +9.9% 1M
Market cap
$34.18B
P/E
40.6x
Revenue (TTM)
$30.68B
Div. yield
–
Medical Supplies Healthcare
1 win

Head to Head

11 decided of 12

Mckesson leads on 8 of the 12 questions below (Mckesson 8, Cencora 2, Medline 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMCKCORMDLNLeader
Larger companyMarket capitalisation $129.46B $69.52B $34.18B MCK
Cheaper on earningsLower P/E, profitable companies only 27.5x 22.6x 40.6x COR
Cheaper on forward earningsLower price / next fiscal year consensus EPS 22.8x 18.8x 26.5x COR
Faster revenue growthRevenue growth, trailing twelve months +8.2% +5.0% — MCK
More profitableNet margin, trailing twelve months 1.1% — 2.7% MDLN
Better return on capitalReturn on invested capital 98.7% — 4.3% MCK
Less leveragedLower net debt / EBITDA 0.4x — 3.2x MCK
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +30.3% -1.8% — MCK
Better 5-year returnAnnualised price return, 5 years +37.5%/yr +23.4%/yr — MCK
Less volatileAnnualised volatility, 1 year 31.4% 33.4% 47.8% MCK
Higher overall scoreMean of the five percentile scores vs peers 58/100 56/100 53/100 MCK

Percentile Scorecard

MCKCORMDLN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMCKCORMDLN
Valuation 65 #10 of 27 54 #13 of 27 78 #54 of 243
Growth 56 #12 of 26 64 #10 of 26 –
Profitability 56 #12 of 26 64 #10 of 26 73 #60 of 222
Financial Health 56 #12 of 26 – 43 #143 of 248
Shareholder Returns 59 #8 of 18 41 #11 of 18 17 #132 of 158
Overall 58 56 53
  • MCK ranked among 27 companies in Healthcare Payers and Distributors
  • COR ranked among 27 companies in Healthcare Payers and Distributors
  • MDLN ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMCKCORMDLNSPY
1 month +12.7%+6.8%+9.9% -2.0%
3 months +26.9%+14.4%+10.4% -2.8%
6 months +45.0%+39.3%+9.1% +2.0%
Year to date +34.4%+6.3%-6.0% +10.6%
1 year +30.3%-1.8%— +12.2%
3 years +143.0%+84.7%— +68.1%
3 years, per year +34.5%+22.7%— +18.9%
5 years +390.5%+186.4%— +61.4%
5 years, per year +37.5%+23.4%— +10.1%
10 years +671.0%+354.9%— +248.5%
10 years, per year +22.7%+16.4%— +13.3%

Risk

MeasureMCKCORMDLNSPY
Volatility, 1Y 31.4%33.4%47.8% 13.6%
Downside volatility, 1Y 27.2%40.0%48.2% 13.9%
Beta vs S&P 500, 1Y -0.180.050.74 1.00
Return / volatility, 1Y 0.97-0.05— 0.90
Max drawdown, 5Y -27.2%-32.6%-36.7% -25.4%
From 52-week high 0.0%-4.2%-21.0% -3.2%
52-week high $1,102.82$374.75$49.99 $779.14
52-week low $725.17$252.74$31.64 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMCKCORMDLN
P/E now vs peer median 27.3xmedian 25.2x 22.6xmedian 25.2x 41.1xmedian 26.5x
P/S now vs peer median 0.3xmedian 0.4x 0.2xmedian 0.4x 1.7xmedian 2.7x
EV/EBITDA now vs peer median 17.4xmedian 14.5x —median 14.5x 21.6xmedian 18.4x
P/FCF now vs peer median 17.9xmedian 16.5x 14.5xmedian 16.5x 27.4xmedian 25.4x
P/B now vs peer median -32.2xmedian 2.7x 18.6xmedian 2.7x 2.7xmedian 2.5x
PEG now vs peer median 1.72median 1.72 —median 1.72 —median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMCKCORMDLN
Revenue $418.79B $337.40B $30.68B
Gross profit $15.37B $13.87B $7.90B
Operating income $6.69B $3.93B $1.74B
Net income $5.43B $3.51B $889.00M
Free cash flow $7.11B – $1.90B
EPS (diluted) $40.27 – $0.64
Cash & equivalents $6.53B $4.88B $2.32B
Total debt $9.21B – $12.58B
Shares (diluted) 116.70M 193.94M 1.32B
Enterprise value $110.83B $69.52B $23.72B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMCKCORMDLN
P/E 27.3x 22.6x 41.1x
P/FCF 17.9x 14.5x 27.4x
P/Operating cash flow 17.0x 14.3x 21.8x
P/S 0.3x 0.2x 1.7x
P/B -32.2x 18.6x 2.7x
P/Tangible book -16.1x 18.6x 8.6x
EV/EBITDA 17.4x – 21.6x
EV/EBIT 19.4x – 35.0x
EV/Revenue 0.3x 0.2x 2.0x
EV/FCF 18.3x – 32.1x
EV/Operating cash flow 17.3x 14.3x 25.6x
PEG (3Y EPS CAGR) 1.72 – –

Growth

14 metrics
MetricMCKCORMDLN
Revenue growth (1Y) 8.2% 5.0% –
Revenue CAGR (3Y) 12.9% 8.8% –
Gross profit growth (1Y) 11.8% 20.8% –
Gross profit CAGR (3Y) 7.6% 15.7% –
Operating income growth (1Y) 27.3% 49.5% –
Operating income CAGR (3Y) 16.1% 18.9% –
Net income growth (1Y) 28.5% 124.0% –
Net income CAGR (3Y) 14.2% 26.3% –
EPS growth (1Y) 24.2% – –
EPS CAGR (3Y) 15.9% – –
Operating cash flow growth (1Y) 9.3% 23.6% –
Operating cash flow CAGR (3Y) 15.2% 7.0% –
Free cash flow growth (1Y) 11.8% – –
Free cash flow CAGR (3Y) 16.3% – –

Profitability

14 metrics
MetricMCKCORMDLN
Gross margin 3.7% – 25.7%
EBITDA margin 1.8% – 9.2%
Operating margin 1.6% – 5.7%
Pretax margin 1.6% – 3.6%
Net margin 1.1% – 2.7%
FCF margin 1.7% – 6.2%
Operating cash flow margin 1.8% 1.4% 7.8%
Return on equity – 101.2% 4.6%
Return on assets 6.0% 4.1% 2.2%
Return on invested capital 98.7% – 4.3%
Return on capital employed 42.0% – 4.8%
Asset turnover 4.6x 3.9x 0.8x
Cash conversion (OCF / net income) 1.4x 1.4x 2.7x
Stock comp / revenue – – 0.4%

Financial Health

11 metrics
MetricMCKCORMDLN
Debt / assets 10.0% – 31.3%
Debt / equity -2.3x – 0.6x
Net debt / EBITDA 0.4x – 3.2x
Debt / FCF 1.3x – 6.6x
Liabilities / assets 104.3% – 51.7%
Equity / assets -4.3% 4.2% 48.3%
Interest coverage 21.9x – –
Current ratio 0.9x 0.9x 4.0x
Quick ratio 0.5x – 2.4x
Cash ratio 0.1x – 1.2x
Altman Z-score 5.83 – 2.70

Shareholder Returns

7 metrics
MetricMCKCORMDLN
Dividend yield 0.3% 0.9% –
Net buyback yield 5.2% – -13.6%
Shareholder yield 5.6% 0.9% -13.6%
Payout ratio (earnings) 7.4% – –
Payout ratio (FCF) 5.6% – –
Dividend growth (1Y) 10.5% – –
Dividend CAGR (3Y) 9.8% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMCKCORMDLN
Forward P/E 22.8xFY2026 18.8xFY2027 26.5xFY2026
EPS, next fiscal year $48.34FY2026 $19.07FY2027 $1.49FY2026
EPS growth, next FY +23.6%FY2026 +6.1%FY2027 +4.2%FY2026
EPS growth, the year after +11.9% +17.4% +9.4%
Revenue, next fiscal year $447.65BFY2026 $328.27BFY2027 $32.69BFY2026
Revenue growth, next FY +11.0%FY2026 -2.7%FY2027 +15.0%FY2026
Revenue growth, the year after +1.5% +19.1% +8.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMCKCORMDLN
Held by institutions 89.1% 94.7% 57.1%
Institutions holding 2,014 1,345 409
Change in shares held, QoQ -0.7% +15.7% +17.9%
Institutions buying 883 542 322
Institutions selling 793 612 69
Buyers to sellers 1.11 0.89 4.67

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MCKCORMDLN
MCK 1.00 0.71 0.24
COR 0.71 1.00 0.25
MDLN 0.24 0.25 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MCK, COR and MDLN?

Mckesson (MCK) is the largest by market capitalisation: Mckesson (MCK) $129.46B, Cencora (COR) $69.52B, Medline (MDLN) $34.18B.

Which stock is cheaper, MCK, COR and MDLN?

Cencora (COR) trades on the lowest price-to-earnings ratio (Mckesson (MCK) 27.5x, Cencora (COR) 22.6x, Medline (MDLN) 40.6x). On next year's consensus earnings, Cencora (COR) is cheapest (Mckesson (MCK) 22.8x, Cencora (COR) 18.8x, Medline (MDLN) 26.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Mckesson (MCK) grew revenue fastest over the trailing twelve months: Mckesson (MCK) +8.2%, Cencora (COR) +5.0%.

Which company is more profitable?

Medline (MDLN) has the highest net margin (Mckesson (MCK) 1.1%, Medline (MDLN) 2.7%). On return on invested capital, Mckesson (MCK) leads (Mckesson (MCK) 98.7%, Medline (MDLN) 4.3%).

Which stock has performed better?

Over the past year Mckesson (MCK) returned the most: Mckesson (MCK) +30.3%, Cencora (COR) -1.8%. Over five years, Mckesson (MCK) compounded fastest (Mckesson (MCK) +37.5%/yr, Cencora (COR) +23.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Mckesson (MCK) 0.00%, Cencora (COR) 0.00%, Medline (MDLN) 0.00%. Cencora (COR) and Medline (MDLN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (Mckesson (MCK) 31.4%, Cencora (COR) 33.4%, Medline (MDLN) 47.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, MCK, COR and MDLN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mckesson (MCK) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.